无码欧美成人av天堂456软件,大胆日本熟妇XXXX,9277在线观看免费播放,4p三个男人让我爽了一夜

全、新、優(yōu)、品、好四大特點：

成對螺旋細(xì)絲蛋白抗體費用 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細(xì)胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊，產(chǎn)品一旦售出，實驗過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時沒有任何的后顧之憂。

成對螺旋細(xì)絲蛋白抗體費用 英文名稱  Anti-PHF/Paired Helical Filaments

中文名稱  成對螺旋細(xì)絲蛋白抗體費用 

別    名 Microtubule-associated protein tau; Neurofibrillary tangle protein; Paired helical filament-tau; PHF-tau; TAU_HUMAN.

產(chǎn)品屬性：

濃    度  1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Cow, Horse

產(chǎn)品類型   一抗  

研究領(lǐng)域    神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) Alzheimer's

蛋白分子量  predicted molecular weight: 79kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated synthetic peptide derived from human Paired Helical Filaments

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

成對螺旋細(xì)絲蛋白抗體費用 產(chǎn)品應(yīng)用   WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 Neuropathology Paired structures that are core constituents of the neurofibrillary tangles of Alzheimer's disease and occur in Down syndrome, Hallervorden-Spatz disease, lead encephalopathy, lipofuscinosis, subacute sclerosing panencephalitis, and tuberous sclerosis.

Function : Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.

Subunit : Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated. Interacts with FKBP4 (By similarity). Binds to CSNK1D. Interacts with SGK1.

Subcellular Location : Cytoplasm, cytosol. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytoskeleton. Cell projection, axon. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.

Post-translational modifications : Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5, GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in the form associated with paired helical filaments (PHF-tau)), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK1 or MARK2), causing detachment from microtubules, and their disassembly. Phosphorylation decreases with age. Phosphorylation within tau/MAP's repeat domain or in flanking regions seems to reduce tAU/MAP's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis. Phosphorylation at Ser-548 by GSK3B reduces ability to bind and stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and BRSK2 in neurons affects ability to bind microtubules and plays a role in neuron polarization. Phosphorylated at Ser-554, Ser-579, Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 by SGK1 mediates microtubule depolymerization and neurite formation in hippocampal neurons. There is a reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces glycosylation by a factor of 2 and 4 respectively. Phosphorylation on Ser-721 is reduced by about 41.5% by GlcNAcylation on Ser-717.

Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.

O-glycosylated. O-GlcNAcylation content is around 8.2%. There is reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces O-GlcNAcylation by a factor of 2 and 4 respectively. O-GlcNAcylation on Ser-717 decreases the phosphorylation on Ser-721 by about 41.5%.

Glycation of PHF-tau, but not normal brain TAU/MAPT. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.

DISEASE : Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer disease brain cerebral cortex leading to an increase in TAU/MAPT phosphorylations.

Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.

Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.

Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. [DISEASE] Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

Defects in MAPT are a cause of Parkinson-dementia syndrome (PARDE) [MIM:260540]. A syndrome characterized by parkinsonism tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei.

Similarity : Contains 4 Tau/MAP repeats.

Database links : UniProtKB/Swiss-Prot: P10636.5

PHF以神經(jīng)原纖維纏結(jié)(neurofibrillary tangles, NFT)存在于神經(jīng)元的胞體;以神經(jīng)毯和性斑存在于受累神經(jīng)元的退化樹突.微管相關(guān)蛋白tau是PHF的主要組成成分.在AD腦中,特別是在PHF結(jié)構(gòu)中的tau被異常過度磷酸化.用磷酸化依賴的特異抗tau抗體檢測,已證明PHF中的tau蛋白至少有21個異常磷酸化位點.

實驗流程：

正在熱銷的相關(guān)產(chǎn)品：

CEA/CD66(Human carcinoembryonic antign) ELISA Kit 人癌胚抗原Multi-class antibodies規(guī)格： 48T

Anti-HOXA10 HOXA10抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh MCM2 染色體維持缺陷蛋白2抗體 規(guī)格 0.1ml

STK(Human serine/threonine protein kinase) ELISA Kit 人絲酸/蘇酸蛋酸酶 96T

RASSF6 英文名稱： RAS家族關(guān)聯(lián)結(jié)構(gòu)域蛋白6抗體 0.2ml

C1orf156 英文名稱： 1號染色體開放閱讀框156抗體 0.2ml

Anti-HOXA10 HOXA10抗體Multi-class antibodies規(guī)格： 0.2ml

HMGB1 human 人高遷移率族蛋白Multi-class antibodies規(guī)格： 48T

Anti-Collagen III 抗Ⅲ型膠原抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh non-muscle Myosin IIA 非平滑肌肌球蛋白2A抗體 規(guī)格 0.2ml

Human amyloid beta peptide 1-40,A Beta1-40 ELISA Kit 人β淀粉樣蛋白1-40 96T

phospho-Tau protein(Ser404) 英文名稱： 磷酸化微管相關(guān)蛋白抗體 0.1ml

phospho-CXCR4 (Ser339) 英文名稱： 磷酸化細(xì)胞表面趨化因子受體4抗體 0.2ml

Anti-Collagen III 抗Ⅲ型膠原抗體Multi-class antibodies規(guī)格： 0.1ml

Anti-IL-15/FITC 熒光素標(biāo)記白介素15抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-PTP-1B/FITC 熒光素標(biāo)記PTP-1B蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh APG7/ATG7 自噬相關(guān)蛋白7抗體 規(guī)格 0.2ml

Rabbit Anti-rat IgG/Gold 膠體金標(biāo)記的兔抗大鼠IgG 0.5ml

GMIP 英文名稱： GEM相互作用蛋白抗體 0.2ml

Rhesus antibody Rh Rabbit Anti-human sIgA/Alexa Fluor 647 Alexa Fluor 647標(biāo)記的兔抗人分泌型IgA 規(guī)格 0.1ml

Anti-PTP-1B/FITC 熒光素標(biāo)記PTP-1B蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml

大鼠瘤病毒16(HPV-16)ELISA試劑盒 96T/48T 試劑盒 組裝/原裝

人酶(CA)免疫試劑盒 Human carbonic anhydrase,CA ELISA Kit

土壤(S-Hg)濃度測試盒 可見分光光度法 50管/48樣

RatTissuefactorpathwayinhibitor,TFPIELISA試劑盒大鼠組織因子途徑抑制物(TFPI)ELISA試劑盒規(guī)格：96T/48T

HumanleukocyteaigenG,HLA-GELISA試劑盒人類白細(xì)胞抗原G(HLA-G)ELISA試劑盒規(guī)格：96T/48T

humannuclearfactorofkappalightpolypeptidegeneenhancerinB-cellsinhibitorepsilon,Nfkbie人B細(xì)胞κ輕肽基因增強(qiáng)子核因子抑制因子ε(Nfkbie)ELISA試劑盒規(guī)格：96T/48T

大鼠補(bǔ)體蛋白3(C3)ELISA 試劑盒 96T/48T 試劑盒 組裝/原裝

人糜蛋白酶免疫試劑盒 Human chymoypsin ELISA Kit

MouseVisceraladipose-specificserineproteaseinhibitor,vaspinELISAKit小鼠內(nèi)臟脂肪特異性絲氨酸蛋白酶抑制劑(vaspin)ELISA試劑盒規(guī)格：96T/48T

石蠟切片組織CASPASE-8蛋白表達(dá)NBT顯色光學(xué)顯微鏡檢測試劑盒10/20次

HumanProteinCELISA試劑盒人蛋白C(ProteinC)ELISA試劑盒規(guī)格：96T/48T

HumahyroidAibody,TAbELISAKit人甲狀腺抗體(TAb)ELISA試劑盒規(guī)格：96T/48T

成對螺旋細(xì)絲蛋白抗體費用 大鼠蛋白酶激活受體2(PAR2)ELISA試劑盒 ，英文名： PAR2 ELISA Kit

Human ICE protease activating factor (IRAP) ELISA Kit 人ICE蛋白酶激活因子(IRAP)ELISA試劑盒

RatLeptin,LEPELISAkit 大鼠瘦素(LEP)ELISA試劑盒 96T/48T 進(jìn)口分裝

CLIAKitforCYFRA21-1(Humancytokeratinfragmeaigen21-1)ELISAKit人細(xì)胞角蛋白21-1片段規(guī)格：48T/96T

細(xì)胞色素P450亞酶CYP2B6(EFC)活性熒光定量檢測試劑盒20次

RatFMS-liketyrosinekinase3,Flt3ELISAKit大鼠FMS樣酪氨酸激酶3(Flt3)ELISA試劑盒規(guī)格：96T/48T

技術(shù)外包服務(wù):

★成對螺旋細(xì)絲蛋白抗體費用 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測序、載體構(gòu)建等

★蛋白工程：原核、哺乳動物蛋白表達(dá)系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細(xì)胞工程：細(xì)胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細(xì)胞培養(yǎng)、細(xì)胞膜制備、穩(wěn)定細(xì)胞株構(gòu)建、細(xì)胞RNAi技術(shù)等等。